Ky Bonnie, Mann Douglas L
Department of Medicine, Division of Cardiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Department of Medicine, Division of Cardiology, Center for Cardiovascular Research, Washington University School of Medicine, St. Louis, Missouri.
JACC Basic Transl Sci. 2020 Apr 16;5(5):501-517. doi: 10.1016/j.jacbts.2020.04.003. eCollection 2020 May.
The coronavirus disease-2019 (COVID-19) pandemic has resulted in a proliferation of clinical trials designed to slow the spread of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Many therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for influenza, Ebola, or for malaria that were developed decades ago and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here, the authors provide a foundation for cardiovascular and cardio-oncology physicians on the front line providing care to patients with COVID-19, so that they may better understand the emerging cardiovascular epidemiology and the biological rationale for the clinical trials that are ongoing for the treatment of patients with COVID-19.
2019年冠状病毒病（COVID-19）大流行导致了大量旨在减缓严重急性呼吸综合征冠状病毒2（SARS-CoV-2）传播的临床试验。许多用于治疗COVID-19患者的治疗药物都是几十年前开发的用于治疗流感、埃博拉或疟疾的 repurposed 疗法，心血管和心脏肿瘤学界可能并不熟悉这些疗法。在此，作者为一线为COVID-19患者提供护理的心血管和心脏肿瘤内科医生提供了一个基础，以便他们能更好地了解新出现的心血管流行病学以及正在进行的治疗COVID-19患者的临床试验的生物学原理。
